-+ 0.00%
-+ 0.00%
-+ 0.00%

Pila Pharma H1 FY26 EBIT loss narrows to SEK 3.85 million; net loss improves to SEK 3.87 million

PUBT·08/27/2026 06:33:23
Listen to the news
Pila Pharma H1 FY26 EBIT loss narrows to SEK 3.85 million; net loss improves to SEK 3.87 million
  • Pila Pharma posted an operating loss of SEK 3.85 million for H1 2026, narrowing from SEK 4.09 million a year earlier.
  • Net loss totaled SEK 3.87 million, improving from SEK 4.1 million; loss per share narrowed to SEK 0.08 from SEK 0.15.
  • Cash flow was SEK -17.97 million, compared with SEK -3.81 million, while cash stood at SEK 3.26 million at June 30.
  • Equity rose to SEK 16.11 million, lifting the solvency ratio to 96% from 33%.
  • Regulatory clearance was secured to run the 12-week PP-CT04 obesity trial of XEN-D0501; CEO Gustav H. Gram flagged higher-dose testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.